Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and what it could mean.
Up 50% in 3 Months, Is This Stock Still a Buy? This biotech's innovative ways might eventually pay off.
The 3 Things That Matter for CRISPR Therapeutics Now As time marches on, the factors that could make or break this stock are becoming crystal clear.
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles During the pandemic-fueled boom of 2020, Cathie Wood's Ark Innovation ETF (
NYSE:ARKK ) was one of the hottest funds on Wall Street, surging nearly 400% off its March 2020 lows. But that euphoria peaked in February 2021.
3 Monster Stocks to Hold for the Next 10 Years These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own.
10 Monster Stocks to Hold for the Next 10 Years Each of these 10 businesses offers a market-leading product or service within an industry that's set to explode.
Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK), while placing a cap on potential gains.
2 Growth Stocks to Buy Hand Over Fist in July These companies are poised to produce fireworks for your portfolio over the coming years.
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
The FDA Shake-Up Continues, And Could Impact Genetic Medicines Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases.
The Best Stocks to Invest $1,000 in Right Now Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit.
